Jak działa semaglutyd? [wideo]

Źródła

1. Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials. Obes Rev. 2023;24(3):e13543. doi:10.1111/obr.13543
2. Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opinion on Pharmacotherapy. 2024;25(5):611-619. doi:10.1080/14656566.2024.2343092
3. Cabral Lopes A, Roque F, Lourenço O, Herdeiro MT, Morgado M. Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database. Expert Opinion on Drug Safety. 2023;22(6):455-461. doi:10.1080/14740338.2023.2172159
4. Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0  mg vs once-daily liraglutide 1.2  mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes & Metabolism. 2020;46(2):100-109. doi:10.1016/j.diabet.2019.101117
5. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The Lancet. 2014;384(9951):1349-1357. doi:10.1016/S0140-6736(14)60976-4
6. Eren-Yazicioglu CY, Yigit A, Dogruoz RE, Yapici-Eser H. Can glp-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol. Front Behav Neurosci. 2021;14:614884. doi:10.3389/fnbeh.2020.614884
7. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmology. Published online July 3, 2024. doi:10.1001/jamaophthalmol.2024.2296
8. Masson W, Lobo M, Barbagelata L, Lavalle-Cobo A, Nogueira JP. Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. Endocrinología, Diabetes y Nutrición. 2024;71(3):124-132. doi:10.1016/j.endinu.2024.01.001
9. McGuire MT, Wing RR, Hill JO. The prevalence of weight loss maintenance among American adults. Int J Obes. 1999;23(12):1314-1319. doi:10.1038/sj.ijo.0801075
10. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.322416.
11. Semaglutide. In: Wikipedia. ; 2024. Accessed July 17, 2024. https://en.wikipedia.org/w/index.php?title=Semaglutide&oldid=1234329674
12. Semaglutyd – medycyna praktyczna. Accessed July 17, 2024. https://www.mp.pl/pacjent/leki/subst.html?id=5893
13. Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol. 2021;12. doi:10.3389/fendo.2021.645563
14. Willoughby D, Hewlings S, Kalman D. Body composition changes in weight loss: strategies and supplementation for maintaining lean body mass, a brief review. Nutrients. 2018;10(12):1876. doi:10.3390/nu10121876
15. Yang W, Wu H, Cai X, et al. Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta‐analysis of randomized clinical trials. Obesity Reviews. 2024;25(6):e13725. doi:10.1111/obr.13725
16. Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410. doi:10.1136/bmj-2023-076410